Decibel Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Decibel Therapeutics's estimated annual revenue is currently $14.6M per year.
- Decibel Therapeutics received $55.0M in venture funding in June 2018.
- Decibel Therapeutics's estimated revenue per employee is $173,452
- Decibel Therapeutics's total funding is $189.2M.
- Decibel Therapeutics's current valuation is $116.1M. (January 2022)
Employee Data
- Decibel Therapeutics has 84 Employees.
- Decibel Therapeutics grew their employee count by 5% last year.
Decibel Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $13.8M | 73 | -39% | $107.3M | N/A |
#2 | $0.2M | 1 | 0% | N/A | N/A |
#3 | $3.1M | 26 | 63% | N/A | N/A |
#4 | $29.6M | 125 | 18% | $351M | N/A |
#5 | $15.8M | 84 | -18% | $312.8M | N/A |
#6 | $235M | 269 | -43% | $340.9M | N/A |
#7 | $2.2M | 28 | 4% | N/A | N/A |
#8 | $6M | 34 | 13% | $176.5M | N/A |
#9 | N/A | 9 | 29% | N/A | N/A |
#10 | $1.8M | 24 | 9% | N/A | N/A |
What Is Decibel Therapeutics?
Decibel Therapeutics is a hearing company focused on discovering and developing new medicines to protect, repair and restore hearing. Hearing loss is the most prevalent form of sensory impairment. It is estimated that 50 million people in the U.S., and 360 million people worldwide, suffer from some type of hearing loss. Hearing disorders affect people of all ages and can have a profound impact on quality of life. By combining recent innovations in hearing science with leading diagnostic tools, biological insights, modeling and therapeutic delivery techniques, Decibel is pioneering a comprehensive approach to defining and treating the underlying biological causes of hearing disorders, and developing a pipeline of breakthrough drugs targeted to specific indications and patients. Founded by the world's preeminent experts in inner ear biology and hearing disorders, Decibel Therapeutics was launched in 2015 by Third Rock Ventures and SR One and is headquartered in Boston, Mass. For more information and to browse career opportunities at Decibel Therapeutics, please visit decibeltx.com.
keywords:Biotechnology,Healthcare,Medical Devices,Medical Diagnostics
$189.2M
Total Funding
84
Number of Employees
$14.6M
Revenue (est)
5%
Employee Growth %
$116.1M
Valuation
N/A
Accelerator
Decibel Therapeutics News
... believes will be a valuable component in cancer-fighting combination therapies. ... Intellia Therapeutics and Decibel Therapeutics.
Decibel Therapeutics is trading at a lower price-to-earnings ratio than AstraZeneca, indicating that it is currently the more affordable of the...
Decibel Therapeutics (NASDAQ:DBTX) Stock Rating Upgraded by Zacks Investment Research. Posted by admin on Apr 14th, 2022.
Decibel Therapeutics, a developer of treatments for hearing loss and balance disorders, has raised $82.2 million in an oversubscribed Series D. The round was led by OrbiMed, with new investors such as BlackRock Health Sciences, Janus Henderson, Casdin Capital and Surveyor Capital also joining. D ...
Other Companies in Boston
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $37.4M | 84 | -10% | N/A |
#2 | $16M | 84 | 4% | N/A |
#3 | $10.9M | 84 | 17% | N/A |
#4 | $16.3M | 84 | 18% | N/A |
#5 | $8.8M | 84 | 58% | N/A |
Decibel Therapeutics Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2015-10-16 | $52.0M | A | Third Rock Ventures LLC | Article |
| 2018-06-20 | $55.0M | C | Multiple | Article |
Decibel Therapeutics Executives
| Name | Title |
|---|---|
| Laurence Reid | CEO |
| Elisabeth Leiderman | Chief Financial Officer and Head of Corporate Development |
| Anna Trask | Chief People, Community and Culture Officer |
| Cynthia Hu | Chief Legal Officer and Corporate Secretary |
| John Keilty | Chief Data Sciences Officer |
| Michael Su | Chief Scientific Officer |
| Laurence Reid | Chief Executive Officer |
| Peter Weber | CMO |
| Paula Cobb | Chief Operating Officer |
| Elisabeth Leiderman | Chief Financial Officer & Head of Corporate Development |
| John Lee | Chief Development Officer |
| Patrick Hyland | EVP, Chief People Officer |
| Elaine Cope | Vice President, Operations |
| Sandra Abbott | Senior Scientist, VP/PD AAV Gene Therapy |
| Adam Palermo | Vice President, Head of Genomics and Computational Biology |
| Joe Burns | Vice President, Discovery |
| Elaine Kernbauer | Vice President, Development Operations |
| Jonathon Whitton | Senior Vice President Clinical Research and Development |
| Heather Wolff | Vice President, Clinical Development Operations |
| Ada Silos | VP Pharmacology |
| Bridget Cleff | Vice President, New Product Planning |
| Patrick Hyland | EVP, Chief People Officer |